• Fatih Dal, Hasan Ökmen, Kıvılcım Ulusan, Semiha Battal Havare, Bağnu Orhan, Şükrü Çolak, Ekrem Ferlengez, and Serkan Sari.
• Ministry of health, Istanbul Training and Research Hospital, Department of General Surgery - Istanbul, Turkey.
• Rev Assoc Med Bras (1992). 2022 Jan 1; 68 (1): 94-99.

ObjectiveOur aim was to investigate the hemogram index parameters and their clinical significance in the evaluation of the inflammatory response of patients with male breast cancer, who are rarely observed in the literature.MethodsIn total, 22 (n=22) healthy male and 28 (n=28) male breast cancer patients without synchronous/metachronous tumors were included in this study. They were grouped as the healthy male control group (Group 1) and the male breast cancer patient group (Group 2). The male breast cancer was divided into two subgroups, namely, early stage [(stage: 0/I/II) (Group 2A)] and late stage [(stage: III/IV) (Group 2B)], and their hemogram index parameters were compared.ResultsA significant (p>0.05) increase was observed in neutrophil/lymphocyte ratio (NLR) and·platelet/lymphocyte ratio (PLR) values in the late stage (Group 2B: stage III/IV) compared to the early stage (Group 2A: stage 0/I/II) and healthy control (Group 1) groups.ConclusionsIn male breast cancer patients, neutrophil/lymphocyte ratio and platelet/lymphocyte ratio values were significantly higher as the stage of cancer increased. These readily available simple tests can be used to evaluate the host's inflammatory response in male breast cancer.

15 keywords...

hide…